NERV

Companies
NASDAQ
Minerva Neurosciences Inc.
Health Care
Price Chart
Overview

About NERV

Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

Market Cap
$22.5M
Volume
12.0K
Avg. Volume
16.8K
P/E Ratio
-0.51492536
Dividend Yield
0.00%
Employees
8.0

Company Information

Exchange
NASDAQ
Sector
Health Care
Industry
Biotechnology
Risk & Correlation Analysis
Market Correlation
1.24
Moderate Correlation
Volatility
High (0.78)
Relative to market

Macro Factor Sensitivities

Interest Rates
Low Sensitivity
Inflation
High Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Medium Sensitivity
Commodity Prices
High Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for NERV.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, NERV shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$22.5M
Volume12.0K
P/E Ratio-0.51
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 13, 2025

PortfolioPilot Analysis

Get AI-powered insights on how NERV fits into your investment strategy and portfolio diversification.

Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025